We are live on ! Find out more
AACP

Advantage Alpha Capital Partners Portfolio holdings

AUM $332M
1-Year Est. Return 12.78%
This Fund
S&P 500
This Quarter Est. Return
+14.19%
1 Year Est. Return
+12.78%
3 Year Est. Return
+79.23%
5 Year Est. Return
+110.24%
10 Year Est. Return
AUM
$528M
AUM Growth
+$52.3M
Cap. Flow
-$3.25M
Cap. Flow %
-0.62%
Top 10 Hldgs %
20.16%
Holding
167
New
74
Increased
51
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
MGNI icon
Magnite
MGNI
+$4M
2
BCPC
Balchem Corp
BCPC
+$3.79M
3
IPAR icon
Interparfums
IPAR
+$3.76M
4
HUBS icon
HubSpot
HUBS
+$3.68M
5
KNF icon
Knife River
KNF
+$3.53M

Sector Composition

Rank Sector Weight
1 Industrials 30.14%
2 Technology 19.61%
3 Financials 12.43%
4 Consumer Discretionary 10.63%
5 Healthcare 10.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HELE icon
76
Helen of Troy
HELE
$667M
$2.81M 0.53%
23,235
+3,684
+19% +$397K
UPWK icon
77
Upwork
UPWK
$1.13B
$2.74M 0.52%
184,401
+4,913
+3% +$63.4K
PAY icon
78
Paymentus
PAY
$4.53B
$2.6M 0.49%
145,564
-77,256
-35% -$1.26M
TNET icon
79
TriNet
TNET
$3.23B
$2.56M 0.49%
21,558
-12,638
-37% -$1.44M
PCOR icon
80
Procore
PCOR
$9.68B
$2.53M 0.48%
36,573
-509
-1% -$31.4K
OMCL icon
81
Omnicell
OMCL
$1.51B
$2.47M 0.47%
65,525
+1,416
+2% +$52.1K
HQY icon
82
HealthEquity
HQY
$7.97B
$2.36M 0.45%
35,524
-60,777
-63% -$4.21M
BOOT icon
83
Boot Barn
BOOT
$4.69B
$2.1M 0.4%
27,409
+580
+2% +$43.6K
LESL icon
84
Leslie's
LESL
$4.97M
$2.02M 0.38%
14,589
-6,548
-31% -$720K
HLIO icon
85
Helios Technologies
HLIO
$2.41B
$1.9M 0.36%
41,950
+867
+2% +$40.1K
ARCT icon
86
Arcturus Therapeutics
ARCT
$432M
$1.59M 0.3%
+50,524
New +$1.2M
TRDA icon
87
Entrada Therapeutics
TRDA
$273M
$1.59M 0.3%
+105,137
New +$1.56M
VYGR icon
88
Voyager Therapeutics
VYGR
$218M
$1.49M 0.28%
+176,871
New +$1.28M
IRWD icon
89
Ironwood Pharmaceuticals
IRWD
$682M
$1.44M 0.27%
+125,705
New +$1.24M
VNDA icon
90
Vanda Pharmaceuticals
VNDA
$320M
$1.43M 0.27%
+339,333
New +$1.37M
ZYME icon
91
Zymeworks
ZYME
$2.02B
$1.42M 0.27%
+136,819
New +$1.09M
MDXG icon
92
MiMedx Group
MDXG
$656M
$1.38M 0.26%
+157,705
New +$1.15M
ALKS icon
93
Alkermes
ALKS
$7.95B
$1.37M 0.26%
+49,530
New +$1.29M
VCYT icon
94
Veracyte
VCYT
$3.48B
$1.27M 0.24%
+46,125
New +$1.11M
ACLX
95
DELISTED
Arcellx
ACLX
$1.26M 0.24%
+22,673
New +$1.02M
SWIM icon
96
Latham Group
SWIM
$833M
$1.25M 0.24%
474,747
+10,220
+2% +$25.3K
DVAX
97
DELISTED
Dynavax Technologies
DVAX
$1.25M 0.24%
+89,087
New +$1.24M
VCEL icon
98
Vericel Corp
VCEL
$2.1B
$1.21M 0.23%
+33,876
New +$1.18M
HALO icon
99
Halozyme
HALO
$12B
$1.11M 0.21%
+29,917
New +$1.13M
IBOC icon
100
International Bancshares
IBOC
$4.41B
$572K 0.11%
+10,535
New +$489K

Similar funds

Advantage Alpha Capital Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Advantage Alpha Capital Partners held 167 positions worth $528M, up 11% from $476M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Advantage Alpha Capital Partners's Q4 2023 filing shows 74 new, 51 increased, 29 reduced and 13 closed positions. Its largest new stake was Magnite: 505,655 shares worth $4.72M. The largest sale was National Instruments Corp, an estimated $9.64M.

By sector, the portfolio is most concentrated in Industrials at 30% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Advantage Alpha Capital Partners's largest Q4 2023 buy was Magnite: 505,655 shares worth $4.72M.
  • Advantage Alpha Capital Partners added most to HubSpot in Q4 2023, an estimated $3.68M increase.
  • Advantage Alpha Capital Partners's biggest Q4 2023 reduction was Construction Partners, cutting an estimated $5.59M.
  • Advantage Alpha Capital Partners fully exited National Instruments Corp in Q4 2023, selling an estimated $9.64M.
  • Advantage Alpha Capital Partners's ten largest holdings make up 20% of its $528M portfolio in Q4 2023.
  • Advantage Alpha Capital Partners opened 74 new positions and closed 13 in Q4 2023.
  • Advantage Alpha Capital Partners's portfolio value rose 11% quarter-over-quarter to $528M.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2023, filed 13 Feb 2024.